I am a licensed radiopharmacist who specializes in the clinical translation and preparation of clinical research radiopharmaceuticals intended for both diagnosing and treating disease. I currently serve as Assistant Attending Radiopharmacist in the Radiochemistry and Imaging Sciences Service at Memorial Sloan Kettering. My primary expertise is in the development of immunoPET and theranostics agents, which include 89Zr labeled antibodies and minibodies, 124I- and 131I-radioiodinated antibodies, 68Ga-labeled peptides, and 177Lu-labeled peptides.
As a healthcare professional in the field of radiopharmacy, the focus of my work is on the safe delivery of promising radiopharmaceuticals for various types of disease. I currently supervise the manufacturing of novel molecular imaging agents in MSK’s state-of-the-art Radiochemistry & Molecular Imaging Probes Core Cyclotron Facility. Additionally, I am actively involved in work with both academic and pharmaceutical industry collaborators focused on early agent development strategies. These strategies ensure that the clinical evaluation of novel agents can progress beyond the first-in-human studies stage, increasing the possibility of the agent becoming the standard of clinical care in the future.
- Clinical Expertise: Radiopharmacy
- Languages Spoken: English; Russian; Ukrainian
- Education: PharmD, Ernest Mario School of Pharmacy, Rutgers University
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more